---
figid: PMC7214667__fmed-07-00124-g0001
figtitle: Janus kinase (JAK)-Signal transducer and activator of transcription (STAT)
  signaling pathway and its inhibition with jakinibs in synovial fibroblasts
organisms:
- Mus musculus
- Rattus norvegicus
- Homo sapiens
pmcid: PMC7214667
filename: fmed-07-00124-g0001.jpg
figlink: pmc/articles/PMC7214667/figure/F1/
number: F1
caption: 'Janus kinase (JAK)-Signal transducer and activator of transcription (STAT)
  signaling pathway and its inhibition with jakinibs in synovial fibroblasts. The
  figure shows direct and indirect signaling pathways, involved in the JAK-STAT signaling
  and their targeting with jakinibs in synovial fibroblasts. Only pathways with mechanistic
  evidence and jakinibs with experimental evidence in synovial fibroblasts are included
  in the figure. Upadacitinib has not yet been experimentally explored in synovial
  fibroblasts and is therefore not shown in the figure. Direct signaling through the
  JAK-STAT pathway can be induced with type I and type II interferons (IFN) and interleukin-6
  (IL-6) family cytokines [oncostatin M (OSM), IL-6] upon ligating their respective
  receptors. This is followed by auto-phosphorylation of distinct JAKs that phosphorylate
  specific subsets of STATs. Tumor necrosis factor (TNF) indirectly activates the
  JAK-STAT pathway by increasing the release of IL-6 and IFN beta (IFNβ) from synovial
  fibroblasts with subsequent autocrine activation of IL-6 family and IFN Type I receptor
  complexes, respectively. sIL-6R: soluble IL-6 receptor; TNFR1: TNF receptor 1; IFNα:
  interferon alpha; NF-κB: nuclear factor-kappa B; AP-1: activator protein 1; TAK1:
  transforming growth factor beta-activated kinase 1; IKK: inhibitory kappa B kinase;
  SOCS3: suppressor of cytokine signaling 3; IRF1: interferon response factor 1; CXCL8-11:
  chemokine (C-X-C motif) ligand 8–11; IP-10: IFN-γ-inducible protein 10; TNFSF13B:
  tumor necrosis factor ligand superfamily member 13B, also known as BAFF, BAFF: B-cell
  activating factor; PIAS3: protein inhibitor of activated STAT3; CCL2: chemokine
  (C-C motif) ligand 2; MCP-1: monocyte chemoattractant protein 1; SAA: serum amyloid
  A; MMP 1,3: matrix metalloproteinase 1,3; ECM: extracellular matrix; INCBO28050:
  baricitinib. The figure was created with BioRender.'
papertitle: Hi-JAKi-ng Synovial Fibroblasts in Inflammatory Arthritis With JAK Inhibitors.
reftext: Blaž Burja, et al. Front Med (Lausanne). 2020;7:124.
year: '2020'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9290091
figid_alias: PMC7214667__F1
figtype: Figure
organisms_ner:
- Mus musculus
- Rattus norvegicus
- Homo sapiens
redirect_from: /figures/PMC7214667__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7214667__fmed-07-00124-g0001.html
  '@type': Dataset
  description: 'Janus kinase (JAK)-Signal transducer and activator of transcription
    (STAT) signaling pathway and its inhibition with jakinibs in synovial fibroblasts.
    The figure shows direct and indirect signaling pathways, involved in the JAK-STAT
    signaling and their targeting with jakinibs in synovial fibroblasts. Only pathways
    with mechanistic evidence and jakinibs with experimental evidence in synovial
    fibroblasts are included in the figure. Upadacitinib has not yet been experimentally
    explored in synovial fibroblasts and is therefore not shown in the figure. Direct
    signaling through the JAK-STAT pathway can be induced with type I and type II
    interferons (IFN) and interleukin-6 (IL-6) family cytokines [oncostatin M (OSM),
    IL-6] upon ligating their respective receptors. This is followed by auto-phosphorylation
    of distinct JAKs that phosphorylate specific subsets of STATs. Tumor necrosis
    factor (TNF) indirectly activates the JAK-STAT pathway by increasing the release
    of IL-6 and IFN beta (IFNβ) from synovial fibroblasts with subsequent autocrine
    activation of IL-6 family and IFN Type I receptor complexes, respectively. sIL-6R:
    soluble IL-6 receptor; TNFR1: TNF receptor 1; IFNα: interferon alpha; NF-κB: nuclear
    factor-kappa B; AP-1: activator protein 1; TAK1: transforming growth factor beta-activated
    kinase 1; IKK: inhibitory kappa B kinase; SOCS3: suppressor of cytokine signaling
    3; IRF1: interferon response factor 1; CXCL8-11: chemokine (C-X-C motif) ligand
    8–11; IP-10: IFN-γ-inducible protein 10; TNFSF13B: tumor necrosis factor ligand
    superfamily member 13B, also known as BAFF, BAFF: B-cell activating factor; PIAS3:
    protein inhibitor of activated STAT3; CCL2: chemokine (C-C motif) ligand 2; MCP-1:
    monocyte chemoattractant protein 1; SAA: serum amyloid A; MMP 1,3: matrix metalloproteinase
    1,3; ECM: extracellular matrix; INCBO28050: baricitinib. The figure was created
    with BioRender.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Osmr
  - Il6ra
  - Tnfrsf1a
  - Tnfrsf1b
  - Osm
  - Ifna
  - Tnf
  - Il6
  - Jak2
  - Tyk2
  - Stat1
  - Stat3
  - Stat2
  - Socs3
  - Nfkb1
  - Saa
  - Ccl2
  - Mcpt1
  - Ccl5
  - Mmp13
  - Mmp3
  - Ifnb1
  - Cxcl9
  - S100a10
  - Cxcl10
  - Cxcl11
  - Pias3
  - Tnfsf13b
  - Il6r
  - Rela
  - Tcf20
  - Mmp1
  - OSMR
  - IFNA1
  - IL6R
  - TNFRSF1A
  - OSM
  - CCM2
  - TNF
  - IL6
  - IFN1@
  - IFNA2
  - IFNA17
  - IFNA4
  - IFNA5
  - IFNA6
  - IFNA7
  - IFNA8
  - IFNA10
  - IFNA13
  - IFNA14
  - IFNA16
  - IFNA21
  - JAK2
  - TYK2
  - STAT1
  - STAT3
  - STAT2
  - SOCS3
  - MAN2C1
  - NFKB1
  - RELA
  - RELB
  - REL
  - NFKB2
  - TCF20
  - SAA1
  - SAA2
  - SAA4
  - CCL2
  - CCL5
  - MMP1
  - MMP3
  - IFNB1
  - CXCL9
  - S100A10
  - EXOSC3
  - CXCL10
  - CXCL11
  - PIAS3
  - TNFSF13B
  - IFNK
  - IFNW1
  - baricitinib A peficitinib A INCBO28050
  - Interferon
---
